Fundraising Fox

Bonum Therapeutics

Seattle, US · Founded 2021 · Delaware corporation · 20 employees on LinkedIn · 6 known investors

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.

BiotechHealthtech

Founders & leadership

Bonum Therapeutics was founded in 2021 by John Mulligan.

JMJohn Mulligan
John MulliganinFounder
NPNeela Patel
Neela PatelinExecutive
DH
Diane HollenbaughinExecutive

Board

SBSamuel Bjork
Samuel BjorkinBoard directorPartner at Digitalis Ventures
MSMonique Schiersing
Monique SchiersinginBoard directorSenior Investment Director at Roche Venture Fund
JMJohn McKearn
John McKearnin𝕏Board directorSenior Advisor at RiverVest Venture Partners, focused on early-stage biotech
KHKarl Handelsman
Karl Handelsmanin𝕏Board directorInvestor at Codon Capital
NW
Nicholas WalrodinBoard directorManaging Partner at American Century Private Investments
MM
Mitchell MutzinBoard director
GAGaurav Aggarwal
Gaurav AggarwalinBoard directorManaging Director at Vivo Capital
SB
Samuel BlackmanBoard director

Investors · 6

RiverVest Venture PartnersSt. Louis · $500K – $3Mvia John McKearn · board
Roche Venture FundBasel · $648K – $3.2M
Vivo CapitalPalo Alto · $10M – $50M
3x5 PartnersreportedPortland
Codon CapitalreportedSan Francisco
Digitalis Venturesreported · 2 sourcesNew York · $100K – $10M

Reported raises · per SEC filings

Form D private placements

$73.1M disclosed across 3 rounds · 2021–2026

▶$26.9MraisedApr 2026 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel BjorkDirector
  • Monique SchiersingDirector
  • Neela PatelExecutive Officer
  • John McKearnDirector
  • Diane HollenbaughExecutive Officer
  • Samuel BlackmanDirector
  • John MulliganExecutive Officer, Director, Promoter
  • Karl HandelsmanDirector
  • Nicholas WalrodDirector
  • Mitchell MutzDirector
  • Gaurav AggarwalDirector
Offering amount
$32.3M
Amount sold
$26.9M
First sale
Apr 2026
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$45MraisedNov 2022 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Karl HandelsmanDirector
  • John MulliganExecutive Officer, Director, Promoter
  • Nicholas WalrodDirector
  • Monique SchiersingDirector
  • John McKearnDirector
  • Samuel BjorkDirector
  • Diane HollenbaughExecutive Officer
  • Neela PatelExecutive Officer
  • Mitchell MutzDirector
Offering amount
$93M
Amount sold
$45M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedDec 2021 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Karl HandelsmanDirector
  • Diane HollenbaughExecutive Officer
  • Neela PatelExecutive Officer
  • John McKearnDirector
  • Monique SchiersingDirector
  • Nicholas WalrodDirector
  • John MulliganExecutive Officer, Director, Promoter
Offering amount
$3.6M
Amount sold
$1.2M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Mirum Pharmaceuticals18 shared keywordsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.

Companies competing with Bonum Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025 - BioSpacebiospace.com · Jun 2025Bonum gets $93 million for conditionally active medicinescen.acs.org · Nov 2022Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies - BioSpacebiospace.com · Nov 2022Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies – GeekWiregeekwire.com · Nov 2022News – Bonum Txbonumtx.com · Sep 2022From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines - Jonathan D Grinstein, 2022liebertpub.com

Frequently asked questions

What does Bonum Therapeutics do?
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.
Who founded Bonum Therapeutics?
Bonum Therapeutics was founded by John Mulligan in 2021.
Who are Bonum Therapeutics's investors?
Bonum Therapeutics's investors include RiverVest Venture Partners, Roche Venture Fund, Vivo Capital, 3x5 Partners, Codon Capital, Digitalis Ventures.
How much funding has Bonum Therapeutics raised?
Bonum Therapeutics has disclosed $73.1M raised across 3 rounds.
Where is Bonum Therapeutics headquartered?
Bonum Therapeutics is headquartered in Seattle, US.